{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:04:25Z","timestamp":1791255865954,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81672452, 81972771 and 81472625"],"award-info":[{"award-number":["81672452, 81972771 and 81472625"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2018B0303110015"],"award-info":[{"award-number":["2018B0303110015"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangzhou Science and Technology Project","award":["201707010354"],"award-info":[{"award-number":["201707010354"]}]},{"name":"Project of Educational Commission of Guangdong Province","award":["2016KTSCX115"],"award-info":[{"award-number":["2016KTSCX115"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>MicroRNAs (miRNAs) show considerable promise as therapeutic agents to improve tumor treatment, as they have been revealed as crucial modulators in tumor progression. However, our understanding of their roles in gastric carcinoma (GC) metastasis is limited. Here, we aimed to identify novel miRNAs involved in GC metastasis and explored their regulatory mechanisms and therapeutic significance in GC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The microRNA expression profiles of GC tumors at different stages and at different metastasis statuses were compared respectively using the stomach adenocarcinoma (STAD) miRNASeq dataset in TCGA. Using the above method, miR-4521 was picked out for further study. miR-4521 expression in GC tissues was examined by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and in situ hybridization (ISH). Highly and lowly invasive cell sublines were established using a repetitive transwell assay. Gain-of-function and loss-of-function analyses were performed to investigate the functions of miR-4521 and its upstream and downstream regulatory mechanisms in vitro and in vivo. Moreover, we investigated the therapeutic role of miR-4521 in a mouse xenograft model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In this study, we found that miR-4521 expression was downregulated in GC tissues compared with adjacent normal tissues and that its downregulation was positively correlated with advanced clinical stage, metastasis status and poor patient prognosis. Functional experiments revealed that miR-4521 inhibited GC cell invasion and metastasis in vitro and in vivo. Further studies showed that hypoxia repressed miR-4521 expression via inducing ETS1 and miR-4521 mitigated hypoxia-mediated metastasis, while miR-4521 inactivated the AKT\/GSK3\u03b2\/Snai1 pathway by targeting IGF2 and FOXM1, thereby inhibiting the epithelial-mesenchymal transition (EMT) process and metastasis. In addition, we demonstrated that therapeutic delivery of synthetic miR-4521 suppressed gastric carcinoma progression in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results suggest an important role for miR-4521 in regulating GC metastasis and hypoxic response of tumor cells as well as the therapeutic significance of this miRNA in GC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12943-020-01295-2","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T02:03:25Z","timestamp":1609898605000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Hypoxia downregulated miR-4521 suppresses gastric carcinoma progression through regulation of IGF2 and FOXM1"],"prefix":"10.1186","volume":"20","author":[{"given":"Shan","family":"Xing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenying","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixue","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoting","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donglan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3232-761X","authenticated-orcid":false,"given":"Min","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"key":"1295_CR1","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.3748\/wjg.v25.i17.2029","volume":"25","author":"L Necula","year":"2019","unstructured":"Necula L, Matei L, Dragu D, Neagu AI, Mambet C, Nedeianu S, Bleotu C, Diaconu CC, Chivu-Economescu M. Recent advances in gastric cancer early diagnosis. World J Gastroenterol. 2019;25:2029\u201344.","journal-title":"World J Gastroenterol"},{"key":"1295_CR2","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nrg2290","volume":"9","author":"W Filipowicz","year":"2008","unstructured":"Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008;9:102\u201314.","journal-title":"Nat Rev Genet"},{"key":"1295_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nrg1990","volume":"8","author":"K Chen","year":"2007","unstructured":"Chen K, Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet. 2007;8:93\u2013103.","journal-title":"Nat Rev Genet"},{"key":"1295_CR4","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/nrg2634","volume":"10","author":"CM Croce","year":"2009","unstructured":"Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10:704\u201314.","journal-title":"Nat Rev Genet"},{"key":"1295_CR5","doi-asserted-by":"publisher","first-page":"6401","DOI":"10.1158\/0008-5472.CAN-10-1346","volume":"70","author":"DM Dykxhoorn","year":"2010","unstructured":"Dykxhoorn DM. MicroRNAs and metastasis: little RNAs go a long way. Cancer Res. 2010;70:6401\u20136.","journal-title":"Cancer Res"},{"key":"1295_CR6","doi-asserted-by":"publisher","first-page":"5761","DOI":"10.1038\/onc.2010.352","volume":"29","author":"WK Wu","year":"2010","unstructured":"Wu WK, Lee CW, Cho CH, Fan D, Wu K, Yu J, Sung JJ. MicroRNA dysregulation in gastric cancer: a new player enters the game. Oncogene. 2010;29:5761\u201371.","journal-title":"Oncogene."},{"key":"1295_CR7","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.1002\/jcp.26514","volume":"233","author":"N Hosseinahli","year":"2018","unstructured":"Hosseinahli N, Aghapour M, Duijf PHG, Baradaran B. Treating cancer with microRNA replacement therapy: a literature review. J Cell Physiol. 2018;233:5574\u201388.","journal-title":"J Cell Physiol"},{"key":"1295_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd.2016.246","volume":"16","author":"R Rupaimoole","year":"2017","unstructured":"Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16:203\u201322.","journal-title":"Nat Rev Drug Discov"},{"key":"1295_CR9","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.4161\/cbt.8.24.10765","volume":"8","author":"AE Erson","year":"2009","unstructured":"Erson AE, Petty EM. miRNAs and cancer: new research developments and potential clinical applications. Cancer Biol Ther. 2009;8:2317\u201322.","journal-title":"Cancer Biol Ther"},{"key":"1295_CR10","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.cell.2009.04.021","volume":"137","author":"J Kota","year":"2009","unstructured":"Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M, Clark KR, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 2009;137:1005\u201317.","journal-title":"Cell."},{"key":"1295_CR11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/nature06487","volume":"451","author":"SF Tavazoie","year":"2008","unstructured":"Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, Massague J. Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008;451:147\u201352.","journal-title":"Nature."},{"key":"1295_CR12","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1517\/14728222.2012.703658","volume":"16","author":"M Rossbach","year":"2012","unstructured":"Rossbach M. MicroRNAs in cancer therapy. Expert Opin Ther Targets. 2012;16:743\u20135.","journal-title":"Expert Opin Ther Targets"},{"key":"1295_CR13","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.ymthe.2017.04.005","volume":"25","author":"G Oshima","year":"2017","unstructured":"Oshima G, Guo N, He C, Stack ME, Poon C, Uppal A, Wightman SC, Parekh A, Skowron KB, Posner MC, et al. In vivo delivery and therapeutic effects of a MicroRNA on colorectal liver metastases. Mol Ther. 2017;25:1588\u201395.","journal-title":"Mol Ther"},{"key":"1295_CR14","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.ymthe.2019.05.020","volume":"27","author":"A Singh","year":"2019","unstructured":"Singh A, Bhattacharyya N, Srivastava A, Pruett N, Ripley RT, Schrump DS, Hoang CD. MicroRNA-215-5p treatment suppresses mesothelioma progression via the MDM2-p53-signaling Axis. Mol Ther. 2019;27:1665\u201380.","journal-title":"Mol Ther"},{"key":"1295_CR15","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/mt.2011.48","volume":"19","author":"P Trang","year":"2011","unstructured":"Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D, Weidhaas JB, Bader AG, Slack FJ. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther. 2011;19:1116\u201322.","journal-title":"Mol Ther"},{"key":"1295_CR16","doi-asserted-by":"publisher","first-page":"5923","DOI":"10.1158\/0008-5472.CAN-10-0655","volume":"70","author":"JF Wiggins","year":"2010","unstructured":"Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D, Bader AG. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 2010;70:5923\u201330.","journal-title":"Cancer Res"},{"key":"1295_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/nm.2284","volume":"17","author":"C Liu","year":"2011","unstructured":"Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011;17:211\u20135.","journal-title":"Nat Med"},{"key":"1295_CR18","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","volume":"18","author":"N van Zandwijk","year":"2017","unstructured":"van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, Clarke S, Huynh Y, Chrzanowska A, Fulham MJ, Bailey DL, et al. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 2017;18:1386\u201396.","journal-title":"Lancet Oncol"},{"key":"1295_CR19","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1136\/gutjnl-2019-318817","volume":"69","author":"L Ding","year":"2020","unstructured":"Ding L, Li Q, Chakrabarti J, Munoz A, Faure-Kumar E, Ocadiz-Ruiz R, Razumilava N, Zhang G, Hayes MH, Sontz RA, et al. MiR130b from Schlafen4(+) MDSCs stimulates epithelial proliferation and correlates with preneoplastic changes prior to gastric cancer. Gut. 2020;69:1750\u201361.","journal-title":"Gut."},{"key":"1295_CR20","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.canlet.2017.06.006","volume":"403","author":"M Deng","year":"2017","unstructured":"Deng M, Zeng C, Lu X, He X, Zhang R, Qiu Q, Zheng G, Jia X, Liu H, He Z. miR-218 suppresses gastric cancer cell cycle progression through the CDK6\/Cyclin D1\/E2F1 axis in a feedback loop. Cancer Lett. 2017;403:175\u201385.","journal-title":"Cancer Lett"},{"key":"1295_CR21","doi-asserted-by":"publisher","first-page":"e1000879","DOI":"10.1371\/journal.pgen.1000879","volume":"6","author":"J Tie","year":"2010","unstructured":"Tie J, Pan Y, Zhao L, Wu K, Liu J, Sun S, Guo X, Wang B, Gang Y, Zhang Y, et al. MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet. 2010;6:e1000879.","journal-title":"PLoS Genet"},{"key":"1295_CR22","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1200\/JCO.2002.20.3.680","volume":"20","author":"A Fyles","year":"2002","unstructured":"Fyles A, Milosevic M, Hedley D, Pintilie M, Levin W, Manchul L, Hill RP. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol. 2002;20:680\u20137.","journal-title":"J Clin Oncol"},{"key":"1295_CR23","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1158\/0008-5472.CAN-03-3196","volume":"64","author":"RA Cairns","year":"2004","unstructured":"Cairns RA, Hill RP. Acute hypoxia enhances spontaneous lymph node metastasis in an orthotopic murine model of human cervical carcinoma. Cancer Res. 2004;64:2054\u201361.","journal-title":"Cancer Res"},{"key":"1295_CR24","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1038\/ncomms6203","volume":"5","author":"T van den Beucken","year":"2014","unstructured":"van den Beucken T, Koch E, Chu K, Rupaimoole R, Prickaerts P, Adriaens M, Voncken JW, Harris AL, Buffa FM, Haider S, et al. Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. Nat Commun. 2014;5:5203.","journal-title":"Nat Commun"},{"key":"1295_CR25","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1476-4598-13-28","volume":"13","author":"C Camps","year":"2014","unstructured":"Camps C, Saini HK, Mole DR, Choudhry H, Reczko M, Guerra-Assuncao JA, Tian YM, Buffa FM, Harris AL, Hatzigeorgiou AG, et al. Integrated analysis of microRNA and mRNA expression and association with HIF binding reveals the complexity of microRNA expression regulation under hypoxia. Mol Cancer. 2014;13:28.","journal-title":"Mol Cancer"},{"key":"1295_CR26","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.1038\/ncomms6202","volume":"5","author":"R Rupaimoole","year":"2014","unstructured":"Rupaimoole R, Wu SY, Pradeep S, Ivan C, Pecot CV, Gharpure KM, Nagaraja AS, Armaiz-Pena GN, McGuire M, Zand B, et al. Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nat Commun. 2014;5:5202.","journal-title":"Nat Commun"},{"key":"1295_CR27","doi-asserted-by":"publisher","first-page":"7243","DOI":"10.1128\/MCB.18.12.7243","volume":"18","author":"M Gupta","year":"1998","unstructured":"Gupta M, Zak R, Libermann TA, Gupta MP. Tissue-restricted expression of the cardiac alpha-myosin heavy chain gene is controlled by a downstream repressor element containing a palindrome of two ets-binding sites. Mol Cell Biol. 1998;18:7243\u201358.","journal-title":"Mol Cell Biol"},{"key":"1295_CR28","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41419-019-1926-1","volume":"10","author":"D Senfter","year":"2019","unstructured":"Senfter D, Samadaei M, Mader RM, Gojo J, Peyrl A, Krupitza G, Kool M, Sill M, Haberler C, Ricken G, et al. High impact of miRNA-4521 on FOXM1 expression in medulloblastoma. Cell Death Dis. 2019;10:696.","journal-title":"Cell Death Dis"},{"key":"1295_CR29","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1080\/1061186X.2017.1306535","volume":"25","author":"B Tian","year":"2017","unstructured":"Tian B, Zhao Y, Liang T, Ye X, Li Z, Yan D, Fu Q, Li Y. Curcumin inhibits urothelial tumor development by suppressing IGF2 and IGF2-mediated PI3K\/AKT\/mTOR signaling pathway. J Drug Target. 2017;25:626\u201336.","journal-title":"J Drug Target"},{"key":"1295_CR30","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.2174\/138161212800672723","volume":"18","author":"M Xue","year":"2012","unstructured":"Xue M, Cao X, Zhong Y, Kuang D, Liu X, Zhao Z, Li H. Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors in cancer therapy: advances and perspectives. Curr Pharm Des. 2012;18:2901\u201313.","journal-title":"Curr Pharm Des"},{"key":"1295_CR31","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41419-018-0262-1","volume":"9","author":"Y Lan","year":"2018","unstructured":"Lan Y, Han J, Wang Y, Wang J, Yang G, Li K, Song R, Zheng T, Liang Y, Pan S, et al. STK17B promotes carcinogenesis and metastasis via AKT\/GSK-3beta\/snail signaling in hepatocellular carcinoma. Cell Death Dis. 2018;9:236.","journal-title":"Cell Death Dis"},{"key":"1295_CR32","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/ncb1173","volume":"6","author":"BP Zhou","year":"2004","unstructured":"Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, Hung MC. Dual regulation of snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol. 2004;6:931\u201340.","journal-title":"Nat Cell Biol"},{"key":"1295_CR33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/emmm.201000107","volume":"3","author":"HJ Park","year":"2011","unstructured":"Park HJ, Gusarova G, Wang Z, Carr JR, Li J, Kim KH, Qiu J, Park YD, Williamson PR, Hay N, et al. Deregulation of FoxM1b leads to tumour metastasis. EMBO Mol Med. 2011;3:21\u201334.","journal-title":"EMBO Mol Med"},{"key":"1295_CR34","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1056\/NEJMcibr1803854","volume":"378","author":"V Tjan-Heijnen","year":"2018","unstructured":"Tjan-Heijnen V, Viale G. The lymph node and the metastasis. N Engl J Med. 2018;378:2045\u20136.","journal-title":"N Engl J Med"},{"key":"1295_CR35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.neulet.2015.05.061","volume":"600","author":"H Zhuang","year":"2015","unstructured":"Zhuang H, Zhang R, Zhang S, Shu Q, Zhang D, Xu G. Altered expression of microRNAs in the neuronal differentiation of human Wharton's jelly mesenchymal stem cells. Neurosci Lett. 2015;600:69\u201374.","journal-title":"Neurosci Lett"},{"key":"1295_CR36","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.1073\/pnas.1604266113","volume":"113","author":"Y Pekarsky","year":"2016","unstructured":"Pekarsky Y, Balatti V, Palamarchuk A, Rizzotto L, Veneziano D, Nigita G, Rassenti LZ, Pass HI, Kipps TJ, Liu CG, Croce CM. Dysregulation of a family of short noncoding RNAs, tsRNAs, in human cancer. Proc Natl Acad Sci U S A. 2016;113:5071\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1295_CR37","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1245\/s10434-018-6626-z","volume":"25","author":"K Chiam","year":"2018","unstructured":"Chiam K, Mayne GC, Watson DI, Woodman RJ, Bright TF, Michael MZ, Karapetis CS, Irvine T, Phillips WA, Hummel R, et al. Identification of microRNA biomarkers of response to Neoadjuvant Chemoradiotherapy in esophageal adenocarcinoma using next generation sequencing. Ann Surg Oncol. 2018;25:2731\u20138.","journal-title":"Ann Surg Oncol"},{"key":"1295_CR38","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41420-019-0167-5","volume":"5","author":"X Feng","year":"2019","unstructured":"Feng X, Yan N, Sun W, Zheng S, Jiang S, Wang J, Guo C, Hao L, Tian Y, Liu S, Sun MZ. miR-4521-FAM129A axial regulation on ccRCC progression through TIMP-1\/MMP2\/MMP9 and MDM2\/p53\/Bcl2\/Bax pathways. Cell Death Dis. 2019;5:89.","journal-title":"Cell Death Dis"},{"key":"1295_CR39","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1615\/CritRevImmunol.2019030168","volume":"38","author":"A Francis","year":"2018","unstructured":"Francis A, Venkatesh GH, Zaarour RF, Zeinelabdin NA, Nawafleh HH, Prasad P, Buart S, Terry S, Chouaib S. Tumor hypoxia: a key determinant of microenvironment hostility and a major checkpoint during the antitumor response. Crit Rev Immunol. 2018;38:505\u201324.","journal-title":"Crit Rev Immunol"},{"key":"1295_CR40","first-page":"4509","volume":"56","author":"M Hockel","year":"1996","unstructured":"Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996;56:4509\u201315.","journal-title":"Cancer Res"},{"key":"1295_CR41","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc704","volume":"2","author":"AL Harris","year":"2002","unstructured":"Harris AL. Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2:38\u201347.","journal-title":"Nat Rev Cancer"},{"key":"1295_CR42","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nature11207","volume":"487","author":"M Montagner","year":"2012","unstructured":"Montagner M, Enzo E, Forcato M, Zanconato F, Parenti A, Rampazzo E, Basso G, Leo G, Rosato A, Bicciato S, et al. SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature. 2012;487:380\u20134.","journal-title":"Nature."},{"key":"1295_CR43","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/ncb1691","volume":"10","author":"MH Yang","year":"2008","unstructured":"Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, Teng SC, Wu KJ. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol. 2008;10:295\u2013305.","journal-title":"Nat Cell Biol"},{"key":"1295_CR44","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.1073\/pnas.0802047105","volume":"105","author":"C Sahlgren","year":"2008","unstructured":"Sahlgren C, Gustafsson MV, Jin S, Poellinger L, Lendahl U. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci U S A. 2008;105:6392\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1295_CR45","doi-asserted-by":"publisher","first-page":"5948","DOI":"10.2174\/1381612822666160713100235","volume":"22","author":"SM Kessler","year":"2016","unstructured":"Kessler SM, Haybaeck J, Kiemer AK. Insulin-like growth factor 2 - the oncogene and its accomplices. Curr Pharm Des. 2016;22:5948\u201361.","journal-title":"Curr Pharm Des"},{"key":"1295_CR46","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1177\/0300060513476585","volume":"41","author":"M Haisa","year":"2013","unstructured":"Haisa M. The type 1 insulin-like growth factor receptor signalling system and targeted tyrosine kinase inhibition in cancer. J Int Med Res. 2013;41:253\u201364.","journal-title":"J Int Med Res"},{"key":"1295_CR47","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ctrv.2017.08.012","volume":"60","author":"JAL Liefers-Visser","year":"2017","unstructured":"Liefers-Visser JAL, Meijering RAM, Reyners AKL, van der Zee AGJ, de Jong S. IGF system targeted therapy: therapeutic opportunities for ovarian cancer. Cancer Treat Rev. 2017;60:90\u20139.","journal-title":"Cancer Treat Rev"},{"key":"1295_CR48","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1038\/s41388-017-0115-x","volume":"37","author":"L Ireland","year":"2018","unstructured":"Ireland L, Santos A, Campbell F, Figueiredo C, Hammond D, Ellies LG, Weyer-Czernilofsky U, Bogenrieder T, Schmid M, Mielgo A. Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer. Oncogene. 2018;37:2022\u201336.","journal-title":"Oncogene."},{"key":"1295_CR49","doi-asserted-by":"crossref","unstructured":"Parra-Guillen ZP, Schmid U, Janda A, Freiwald M, Troconiz IF. Model-informed dose selection for Xentuzumab, a dual insulin-like growth factor-I\/II-neutralizing antibody. Clin Pharmacol Ther. 2020;107:597-606.","DOI":"10.1002\/cpt.1648"},{"key":"1295_CR50","doi-asserted-by":"publisher","first-page":"4329","DOI":"10.1158\/0008-5472.CAN-11-0640","volume":"71","author":"P Raychaudhuri","year":"2011","unstructured":"Raychaudhuri P, Park HJ. FoxM1: a master regulator of tumor metastasis. Cancer Res. 2011;71:4329\u201333.","journal-title":"Cancer Res"},{"key":"1295_CR51","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1158\/0008-5472.CAN-16-3566","volume":"77","author":"AL Gartel","year":"2017","unstructured":"Gartel AL. FOXM1 in Cancer: interactions and vulnerabilities. Cancer Res. 2017;77:3135\u20139.","journal-title":"Cancer Res"},{"key":"1295_CR52","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1158\/1078-0432.CCR-16-0742","volume":"23","author":"MD Xu","year":"2017","unstructured":"Xu MD, Wang Y, Weng W, Wei P, Qi P, Zhang Q, Tan C, Ni SJ, Dong L, Yang Y, et al. A positive feedback loop of lncRNA-PVT1 and FOXM1 facilitates gastric Cancer growth and invasion. Clin Cancer Res. 2017;23:2071\u201380.","journal-title":"Clin Cancer Res"},{"key":"1295_CR53","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/1479-5876-11-204","volume":"11","author":"X Li","year":"2013","unstructured":"Li X, Qiu W, Liu B, Yao R, Liu S, Yao Y, Liang J. Forkhead box transcription factor 1 expression in gastric cancer: FOXM1 is a poor prognostic factor and mediates resistance to docetaxel. J Transl Med. 2013;11:204.","journal-title":"J Transl Med"},{"key":"1295_CR54","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.ctrv.2014.09.005","volume":"40","author":"H Stegeman","year":"2014","unstructured":"Stegeman H, Span PN, Kaanders JH, Bussink J. Improving chemoradiation efficacy by PI3-K\/AKT inhibition. Cancer Treat Rev. 2014;40:1182\u201391.","journal-title":"Cancer Treat Rev"},{"key":"1295_CR55","doi-asserted-by":"publisher","first-page":"5843","DOI":"10.1038\/s41388-018-0392-z","volume":"37","author":"Q Meng","year":"2018","unstructured":"Meng Q, Shi S, Liang C, Liang D, Hua J, Zhang B, Xu J, Yu X. Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt\/GSK3beta\/snail signaling. Oncogene. 2018;37:5843\u201357.","journal-title":"Oncogene."}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-020-01295-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12943-020-01295-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-020-01295-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T02:10:42Z","timestamp":1609899042000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-020-01295-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,6]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1295"],"URL":"https:\/\/doi.org\/10.1186\/s12943-020-01295-2","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,6]]},"assertion":[{"value":"13 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research was approved by the Institutional Review Board of Guangzhou Medical University and written informed consent was provided by all patients. All animal studies were approved by the Institutional Animal Care and Use Committee (IACUC) of Guangzhou Medical University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agree for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}